iBio Inc.

Pipeline

iBio has demonstrated the feasibility of developing and producing a wide range of products that are available for license along with the technology to bring them to patients.

Pipeline

IBIO-CFB03

iBio is developing a proprietary therapeutic product for the treatment of idiopathic pulmonary fibrosis (IPF), systemic scleroderma and other fibrotic diseases

View IBIO-CFB03
Phase completed
not started
not started
not started
not started
not started
Preclinical Phase 1 Phase 2a Phase 2b Phase 3 Market

iBio Technology

The iBio Technology platform is a proprietary gene expression technology that causes non-transgenic plants to rapidly produce high levels of target proteins and has been validated across a wide range of applications in both vaccines and biotherapeutics.

Learn more

Learn More About Partnerships

iBio is establishing partnerships through iBio Technology platform licensing arrangements and product collaborations.

Interested in Becoming a Partner?